image credit- shutterstock
Japan-based PRISM BioLab, a leading discovery and development biotechnology company designing small molecule inhibitors of protein-protein interaction (PPI) targets, has entered into a drug discovery collaboration with Elix, Inc.
This partnership will accelerate research on these challenging molecular targets by combining PRISM BioLab's proprietary peptide mimetic technology for controlling protein-protein interactions with Elix's cutting-edge artificial intelligence (AI) drug discovery platform.
In drug discovery, generating a clinical candidate molecule typically takes long time and requires synthesis of hundreds to thousands of compounds, making research and development efficiency a critical challenge.
Through this partnership, PRISM BioLab's proprietary small molecule peptide-mimetic PepMetics technology will be integrated with Elix's AI drug discovery platform "Elix Discovery™." This collaboration will expand the AI search range to include previously unconsidered small molecules, enabling efficient identification of promising compounds for traditionally difficult targets and accelerating the creation of breakthrough drug candidates.
By leveraging both companies' AI capabilities and medicinal chemistry expertise, the partnership aims to reduce time and costs and improve success rate of drug discovery, ultimately delivering innovative treatments for unmet medical needs.
